Cubicin Outcomes Registry and Experience (CORE) Methodology

• Published in: The American journal of medicine Vol. 120; no. 10; pp. S4 - S5
• Main Authors: Rolston, Kenneth V.I., MD, Segreti, John, MD, Lamp, Kenneth C., PharmD, Friedrich, Lawrence V., PharmD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2007; Elsevier Sequoia S.A
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Bacteremia; Bacteria; Daptomycin; Daptomycin - pharmacology; Daptomycin - therapeutic use; Gram-Negative Bacteria - drug effects; Gram-Negative Bacterial Infections - drug therapy; Heart; Humans; Infections; Inflammatory diseases; Internal Medicine; Product Surveillance, Postmarketing; Registries; Right-sided endocarditis; Skin and skin-structure infections; Skin Diseases, Infectious - drug therapy; Therapy; Time Factors; Treatment Outcome; United States > US; Right-sided endocarditis; Skin and skin-structure infections; Bacteremia; Daptomycin
• ISSN: 0002-9343; 1555-7162
• DOI: 10.1016/j.amjmed.2007.07.008

Abstract The Cubicin Outcomes Registry and Experience (CORE), was designed to retrospectively collect the real-world postmarking experience of patients who received daptomycin. A standardized case report form was used by trained investigators from 45 institutions across the United States. Data on 1,160 patients from November 2003 until December 2004 were collected on demographics, infections, treatments and outcomes at the end of daptomycin therapy. The data from CORE 2004 provide insight into the early clinical use of daptomycin.